AzTrials
AzTrials

Cement SyndromeNCT07669376

Role of Inferior Vena Cava Dispensability Index in Predicting Hypotension of Cement Syndrome in Hip Replacement Surgery Under General Anaesthesia

An observational study of Cement Syndrome and Hypotension and Shock, run by Ain Shams University at 1 site in Egypt.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

The aim of the study is to evaluate ICV distensibility index for predicting the incidence of hypotension following cementation in orthopedic hip replacement surgery in patient undergoing general anaesthesia Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cement Syndrome, Hypotension and Shock
What is being tested?
Ultrasound measurement of IVC
Type of treatment
Medical device
How many people
30 participants
Where
1 siteEgypt
Study dates
20 Dec 2025to 20 Jun 2026
How long will I take part?
30 Days
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients will be selected from primary care clinic who are scheduled for Hip Replacement Surgery

Who may be able to join

  • participants must be 18 years of age or older and provide written consent. Patients scheduled for elective hip replacement surgery under general anaesthesia with an American Society of Anesthesiologists (ASA) physical status of I or III based on preoperative assessment.

Who cannot join

  • ▪ Patient refusal to participate.
  • ASA status IV or above.
  • Patients with BMI more than 30 kg/m².
  • Pre-existing hypotension, cardiac disease (such as heart failure or coronary artery disease), pulmonary disease (such as chronic obstructive pulmonary disease), renal disease (such as chronic kidney disease), hepatic disease (such as cirrhosis), coagulopathy or bleeding disorders, pregnancy or lactation, severe intra-operative blood loss requiring blood transfusion.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Ain Shams University

    Cairo, Abbassia, 00202

Other trials in Egypt

About this study

The aim of the study is to evaluate ICV distensibility index for predicting the incidence of hypotension following cementation in orthopedic hip replacement surgery in patient undergoing general anaesthesia

Read the detailed description

Preoperative Settings:

Patients scheduled for elective hip replacement surgeries involving cementation at Ain Shams University Surgery Hospital will be identified and those meeting the inclusion criteria will be approached and enrolled after providing informed consent.

Patients will be confirmed to have fasted for 8 hours before surgery. Medical history will be taken, examinations performed, and laboratory results will be reviewed. A wide bore intravenous line (18-gauge) will be secured, and standard monitoring (ECG, blood pressure measurement, and pulse oximetry) will be applied.

Baseline blood pressure, heart rate, and mean arterial pressure will be recorded.

Intraoperative procedure:

To induce general anaesthesia, we will be using fentanyl (1-2 μg/kg), propofol (1.5-2 mg/kg) and non-depolarizing muscle relaxants (rocuronium or cis-atracurium) according to age, weight, chronic organ function and the needs of the surgery.

All patients are monitored continuously using ECG, pulse oximetry and capnography starting from the beginning of manual ventilation. Ventilatory parameters adjusted to PCO2 <40 mmHg (respiratory rate 12 breaths per minute,), with a tidal volume of 6 to 8 ml/kg, positive end-expiratory pressure (PEEP) of 6 cmH2O and inspired oxygen fraction (FiO2) of 50.

Noninvasive blood pressure measurements (mean arterial pressure (MAP) are obtained at 10 min intervals although the operation, an additional measurement is obligatory 2 min after induction, drug administration and during measurement of IVC-DI and 5 min pre- and post-cementing for 15 min, all measurements will be performed in the semi-recumbent position (head elevated 30°).

The inferior vena cava will be visualized in B-mode using ultrasound machine with Low-frequency curvilinear probe (2-5 MHz) or phased-array probe while patient in supine position the probe will be placed in subxiphoid (subcoastal) area, just below the sternum (from a longitudinal paramedian subxiphoid view). IVC can be differentiated from the aorta utilizing pulse wave Doppler. With M-mode imaging, done 2 to 3 cm distant to the right atrium, The last section of the vein, which is proximal to the hepatic vein inflow and 0.5-3 cm from the right atrium, will be selected, with Use of the callipers to measure the maximum IVC diameter (Dmax) during inspiration and the minimum IVC diameter (Dmin) during expiration. Then the IVC distensibility index is calculated and recorded using the formula: IVC distensibility index = [(maximum diameter on inspiration-minimum

diameter on expiration)/minimum diameter on expiration (Lujan Varas et al, 2015). All IVC measurements are taken post intubation 3 times and the mean value recorded. Patients will be divided into two groups.

Group A: those who develop hypotension post cementation. Group B: those who do not develop hypotension post cementation. In the study Hypotension will be defined as MAP < 60 mmHg or a decrease in SBP by > 20% from baseline. In case of persistent mean arterial pressure less than 55 mmHg, a 6 mg dose of ephedrine will be titrated. After two doses of ephedrine, another fluid bolus of 5 ml/kg will be given, followed by another dose of ephedrine until hypotension is corrected.

The primary outcome:

Cut off value of IVC-DI at which we can predict the incidence of hypotension following cementing in orthopedic surgery.

Secondary outcomes Intra-operative hemodynamic, the need of vasoactive drug administration, and the amount of fluid administered.

Being tested
Ultrasound measurement of IVC
Medical subject headings
Hypotension, Shock

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ultrasound measurement of IVCDevice

    Ultrasound measurement of IVC to calculate IVC Dispensability index.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cut off value of IVC-DI at which we can predict the incidence of hypotension following cementing in orthopedic surgery.

    Cut off value of IVC-DI at which we can predict the incidence of hypotension following cementing in orthopedic surgery.

    Measured: All IVC measurements are taken 10 minutes post intubation

Secondary outcomes (3)
  1. Intra-operative hemodynamic(blood pressure)

    In the study Hypotension will be defined as MAP < 60 mmHg or a decrease in SBP by > 20% from baseline.

    Measured: At 10 minutes intervals all through the operation, an additional measurement is obligatory 2 minutes after induction, drug administration and during measurement of IVC-DI and 5 minutes pre- and post-cementing for 15 minutes

  2. The need of vasoactive drug administration

    In case of persistent(>5minutes) mean arterial pressure less than 55 mmHg, a 6 mg dose of ephedrine will be titrated.

    Measured: Post cement insertion for 30 minutes

  3. The Amount of Fluid administered.

    After two doses of ephedrine, another fluid bolus of 5 ml/kg will be given, followed by another dose of ephedrine until hypotension is corrected.

    Measured: Post cement insertion for 30 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jun 2026
  2. Study start20 Dec 2025
  3. Primary completion20 Jun 2026 (estimated)
  4. Study completion20 Jun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
30 participants (estimated)
Target duration
30 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT07669376
Sponsor's protocol ID
MS 724/2025
Status last verified
May 2026
First submitted
20 May 2026
Last updated
25 Jun 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in